Reviewing Spectral AI (NASDAQ:MDAI) & Competitive Technologies (OTCMKTS:CTTC)

Spectral AI (NASDAQ:MDAI) and Competitive Technologies (OTCMKTS:CTTC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Profitability

This table compares Spectral AI and Competitive Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-51.97%	N/A	-8.69%
Competitive Technologies	N/A	N/A	N/A

Institutional and Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. 30.7% of Spectral AI shares are owned by insiders. Comparatively, 17.5% of Competitive Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Spectral AI and Competitive Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$27.55 million	1.80	-$15.31 million	($0.69)	-2.70
Competitive Technologies	N/A	N/A	N/A	N/A	N/A

Competitive Technologies has lower revenue, but higher earnings than Spectral AI.

Analyst Ratings

This is a summary of recent ratings and price targets for Spectral AI and Competitive Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	1	0	3.00
Competitive Technologies	0	0	0	0	0.00

Spectral AI currently has a consensus target price of $3.50, suggesting a potential upside of 88.17%. Given Spectral AI’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Spectral AI is more favorable than Competitive Technologies.

Summary

Spectral AI beats Competitive Technologies on 6 of the 8 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.